FDA Approves TAFINLAR — Novartis Pharmaceuticals Corporation

Novartis faces heightened competitive pressure as the FDA approves generic Dabrafenib mesylate for oral use, threatening to undermine the revenue of the company's branded TAFINLAR franchise.